Clinical Observation of Tongxinluo Capsules Combined with Rosuvastatin in the Treatment of Coronary Heart Disease
Objective To investigate the clinical efficacy of Tongxinluo Capsules combined with rosuvastatin in the treatment of coronary heart disease(CHD),and the effect on toll-like receptor 4(TLR-4)mNRA and nuclear factor-κB(NF-κB)mNRA in patients with CHD.Methods A total of 100 patients with CHD admitted to the hospital from May 2021 to May 2023 were selected and randomly divided into the observation group and the control group by the random number table method,with 50 cases in each group.The patients in the two groups were treated with rosuvastatin,on this basis,the patients in the observation group were treated with Tongxinluo Capsules.Both groups were treated for 28 d.Results The total effective rate in the observation group was 96.00%,which was significantly higher than 72.00%in the control group(P<0.05).After treatment,the levels of cardiac troponin T(CTnT),creatine kinase isoenzyme(CK-MB),total cholesterol(TC),triglycerides(TG),left ventricular end-diastolic diameter(LVEDd),and left ventricular end-systolic diameter(LVESd)in the two groups significantly decreased,while the left ventricular ejection fraction(LVEF)in the two groups significantly increased,and the improvement of the above indicators in the observation group was significantly better than that in the control group(P<0.05).After treatment,the expression levels of TLR-4 mNRA and NF-κB mNRA in the two groups significantly decreased,and those in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions was comparable between the observation group and the control group(10.00%vs.6.00%,P>0.05).Conclusion Tongxinluo Capsules combined with rosuvastatin have good efficacy and safety in the treatment of CHD,which can regulate the expression levels of TLR-4 mNRA and NF-κB mNRA,and improve serological and cardiac function indexes.
万方数据
维普
